Riccardo C Bonadonna

List of Publications by Year in Descending Order

132 papers	7,435 citations	36 h-index	85 g-index
140 ext. papers	8,186 ext. citations	6.6 avg, IF	5.13 L-index

#	Paper	IF	Citations
132	SARS-CoV-2 Spike protein is not pro-inflammatory in human primary macrophages: endotoxin contamination and lack of protein glycosylation as possible confounders.. *Cell Biology and Toxicology*, **2022**, 1	7.4	1
131	Role of monogenic diabetes genes on beta cell function in Italian patients with newly diagnosed type 2 diabetes. The Verona Newly Diagnosed Type 2 Diabetes Study (VNDS) 13.. *Diabetes and Metabolism*, **2022**, 101323	5.4	0
130	Empagliflozin does not reverse lipotoxicity-induced impairment in human myeloid angiogenic cell bioenergetics.. *Cardiovascular Diabetology*, **2022**, 21, 27	8.7	
129	Exploring the determinants of ethnic differences in insulin clearance between men of Black African and White European ethnicity. *Acta Diabetologica*, **2021**, 1	3.9	0
128	MG53 marks poor beta cell performance and predicts onset of type 2 diabetes in subjects with different degrees of glucose tolerance. *Diabetes and Metabolism*, **2021**, 48, 101292	5.4	0
127	Ethnic differences in beta cell function occur independently of insulin sensitivity and pancreatic fat in black and white men. *BMJ Open Diabetes Research and Care*, **2021**, 9,	4.5	7
126	Glycaemic Control with Insulin Glargine 300 U/mL in Individuals with Type 2 Diabetes and Chronic Kidney Disease: A REALI European Pooled Data Analysis. *Diabetes Therapy*, **2021**, 12, 1159-1174	3.6	2
125	Glomerular filtration rate decline in T2DM following diagnosis. The Verona newly diagnosed diabetes study-12. *Diabetes Research and Clinical Practice*, **2021**, 175, 108778	7.4	1
124	Effect of coffee and cocoa-based confectionery containing coffee on markers of cardiometabolic health: results from the pocket-4-life project. *European Journal of Nutrition*, **2021**, 60, 1453-1463	5.2	3
123	Metabolomic Changes after Coffee Consumption: New Paths on the Block. *Molecular Nutrition and Food Research*, **2021**, 65, e2000875	5.9	10
122	Changes induced by metabolic surgery on the main components of glucose/insulin system in patients with diabetes and obesity. *Acta Diabetologica*, **2021**, 58, 513-516	3.9	
121	Glucose Tolerance Stages in Cystic Fibrosis Are Identified by a Unique Pattern of Defects of Beta-Cell Function. *Journal of Clinical Endocrinology and Metabolism*, **2021**, 106, e1793-e1802	5.6	6
120	Common Variants Associated to Type 2 Diabetes in the Italian Population. *Open Journal of Endocrine and Metabolic Diseases*, **2021**, 11, 24-42	0.1	1
119	Similar glycaemic control and risk of hypoglycaemia with patient- versus physician-managed titration of insulin glargine 300 U/mL across subgroups of patients with T2DM: a post hoc analysis of ITAS. *Acta Diabetologica*, **2021**, 58, 789-796	3.9	
118	Impact of Age on the Effectiveness and Safety of Insulin Glargine 300 U/mL: Results from the REALI European Pooled Data Analysis. *Diabetes Therapy*, **2021**, 12, 1073-1097	3.6	0
117	Effect of Coffee and Cocoa-Based Confectionery Containing Coffee on Markers of DNA Damage and Lipid Peroxidation Products: Results from a Human Intervention Study. *Nutrients*, **2021**, 13,	6.7	1
116	Underestimation of hypoglycaemia using patients' diaries compared with downloaded glucometer data: an ITAS post hoc analysis. *Diabetes, Obesity and Metabolism*, **2021**,	6.7	0

115	Effect of different patterns of consumption of coffee and a cocoa-based product containing coffee on the nutrikinetics and urinary excretion of phenolic compounds. *American Journal of Clinical Nutrition*, **2021**,	7	2
114	A performance score of the quality of inpatient diabetes care is a marker of clinical outcomes and suggests a cause-effect relationship between hypoglycaemia and the risk of in-hospital mortality. *Diabetes/Metabolism Research and Reviews*, **2020**, 36, e3347	7.5	1
113	Prevalence of orthorexic traits in type 2 diabetes mellitus: at the crossroads between nutritional counseling and eating disorders. *Acta Diabetologica*, **2020**, 57, 1117-1119	3.9	5
112	Insulin clearance as the major player in the hyperinsulinaemia of black African men without diabetes. *Diabetes, Obesity and Metabolism*, **2020**, 22, 1808-1817	6.7	9
111	Comparable efficacy with similarly low risk of hypoglycaemia in patient- vs physician-managed basal insulin initiation and titration in insulin-naïve type 2 diabetic subjects: The Italian Titration Approach Study. *Diabetes/Metabolism Research and Reviews*, **2020**, 36, e3304	7.5	6
110	Absorption, Pharmacokinetics, and Urinary Excretion of Pyridines After Consumption of Coffee and Cocoa-Based Products Containing Coffee in a Repeated Dose, Crossover Human Intervention Study. *Molecular Nutrition and Food Research*, **2020**, 64, e2000489	5.9	6
109	Rationale and methodology for a European pooled analysis of postmarketing interventional and observational studies of insulin glargine 300 U/mL in diabetes: protocol of REALI project. *BMJ Open* , **2020**, 10, e033659	3	3
108	Angelo Gnudi (1931–2020). *L Endocrinologo*, **2020**, 21, 239-240	0	
107	Chronic complications in patients with newly diagnosed type 2 diabetes: prevalence and related metabolic and clinical features: the Verona Newly Diagnosed Type 2 Diabetes Study (VNDS) 9. *BMJ Open Diabetes Research and Care*, **2020**, 8,	4.5	16
106	Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: potential relevance to prevention of cardiovascular events. *Cardiovascular Diabetology*, **2020**, 19, 46	8.7	22
105	Central role of the β-cell in driving regression of diabetes after liver transplantation in cirrhotic patients. *Journal of Hepatology*, **2019**, 70, 954-962	13.4	11
104	Quantification of epicardial fat with cardiac CT angiography and association with cardiovascular risk factors in symptomatic patients: from the ALTER-BIO (Alternative Cardiovascular Bio-Imaging markers) registry. *Diagnostic and Interventional Radiology*, **2019**, 25, 35-41	3.2	21
103	Ethnic differences in intrahepatic lipid and its association with hepatic insulin sensitivity and insulin clearance between men of black and white ethnicity with early type 2 diabetes. *Diabetes, Obesity and Metabolism*, **2019**, 21, 2163-2168	6.7	13
102	Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospective study. *Diabetes, Obesity and Metabolism*, **2019**, 21, 1886-1894	6.7	12
101	Associations Between Pancreatic Lipids and β-Cell Function in Black African and White European Men With Type 2 Diabetes. *Journal of Clinical Endocrinology and Metabolism*, **2019**, 104, 1201-1210	5.6	10
100	Italian Titration Approach Study (ITAS) with insulin glargine 300 U/mL in insulin-naïve type 2 diabetes: Design and population. *Nutrition, Metabolism and Cardiovascular Diseases*, **2019**, 29, 496-503	4.5	6
99	Dysfunctional eating in type 2 diabetes mellitus: A multicenter Italian study of socio-demographic and clinical associations. *Nutrition, Metabolism and Cardiovascular Diseases*, **2019**, 29, 983-990	4.5	4
98	Loss of ZnT8 function protects against diabetes by enhanced insulin secretion. *Nature Genetics*, **2019**, 51, 1596-1606	36.3	45

97	Vitamin D affects insulin sensitivity and β-cell function in obese non-diabetic youths. *European Journal of Endocrinology*, **2019**, 181, 439-450	6.5	12
96	"IGT-like" status in normoglucose tolerant obese children and adolescents: the additive role of glucose profile morphology and 2-hours glucose concentration during the oral glucose tolerance test. *International Journal of Obesity*, **2019**, 43, 1363-1369	5.5	2
95	Hypoglycaemia as a function of HbA1c in type 2 diabetes: Insulin glargine 300 U/mL in a patient-level pooled analysis of EDITION 1, 2 and 3. *Diabetes, Obesity and Metabolism*, **2019**, 21, 715-719	6.7	4
94	Ethnic differences in insulin secretory function between black African and white European men with early type 2 diabetes. *Diabetes, Obesity and Metabolism*, **2018**, 20, 1678-1687	6.7	16
93	Methods to Assess In Vivo Insulin Sensitivity and Insulin Secretion. *Endocrinology*, **2018**, 1-51	0.1	
92	Switching to insulin glargine 300 U/mL: Is duration of prior basal insulin therapy important?. *Diabetes Research and Clinical Practice*, **2018**, 142, 19-25	7.4	10
91	Claimed effects, outcome variables and methods of measurement for health claims on foods related to the gastrointestinal tract proposed under regulation (EC) 1924/2006. *International Journal of Food Sciences and Nutrition*, **2018**, 69, 771-804	3.7	4
90	Claimed effects, outcome variables and methods of measurement for health claims proposed under Regulation (EC) 1924/2006 in the framework of bone health. *PharmaNutrition*, **2018**, 6, 17-36	2.9	3
89	Claimed effects, outcome variables and methods of measurement for health claims on foods proposed under Regulation (EC) 1924/2006 in the area of oral health. *NFS Journal*, **2018**, 10, 10-25	6.5	5
88	Claimed effects, outcome variables and methods of measurement for health claims on foods proposed under European Community Regulation 1924/2006 in the area of appetite ratings and weight management. *International Journal of Food Sciences and Nutrition*, **2018**, 69, 389-409	3.7	10
87	A renal genetic risk score (GRS) is associated with kidney dysfunction in people with type 2 diabetes. *Diabetes Research and Clinical Practice*, **2018**, 144, 137-143	7.4	
86	Methods to Assess In Vivo Insulin Sensitivity and Insulin Secretion. *Endocrinology*, **2018**, 317-367	0.1	1
85	GP/EFSA/NUTRI/2014/01 Scientific substantiation of health claims made on food: collection, collation and critical analysis of information in relation to claimed effects, outcome variables and methods of measurement. *EFSA Supporting Publications*, **2018**, 15, 1272E	1.1	1
84	Thromboxane-Dependent Platelet Activation in Obese Subjects with Prediabetes or Early Type 2 Diabetes: Effects of Liraglutide- or Lifestyle Changes-Induced Weight Loss. *Nutrients*, **2018**, 10,	6.7	14
83	Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12-month randomized controlled trial in patients with type 2 diabetes. *Cardiovascular Diabetology*, **2017**, 16, 27	8.7	26
82	Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial. *Diabetes, Obesity and Metabolism*, **2017**, 19, 1408-1415	6.7	21
81	Lixisenatide as add-on treatment among patients with different β-cell function levels as assessed by HOMA-β index. *Diabetes/Metabolism Research and Reviews*, **2017**, 33, e2897	7.5	8
80	Identification of an early transcriptomic signature of insulin resistance and related diseases in lymphomonocytes of healthy subjects. *PLoS ONE*, **2017**, 12, e0182559	3.7	6

79	Bioavailability of Bergamot (Citrus bergamia) Flavanones and Biological Activity of Their Circulating Metabolites in Human Pro-Angiogenic Cells. *Nutrients*, **2017**, 9,	6.7	19
78	Claimed Effects, Outcome Variables and Methods of Measurement for Health Claims Proposed Under European Community Regulation 1924/2006 in the Framework of Maintenance of Skin Function. *Nutrients*, **2017**, 10,	6.7	4
77	Stearic acid at physiologic concentrations induces in vitro lipotoxicity in circulating angiogenic cells. *Atherosclerosis*, **2017**, 265, 162-171	3.1	13
76	Effects of Liraglutide on Weight Loss, Fat Distribution, and Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes. *Diabetes Care*, **2017**, 40, 1556-1564	14.6	45
75	Variabilit genetica di PCSK9 e HMGCR e rischio di malattia cardiovascolare e di diabete. *L Endocrinologo*, **2017**, 18, 43-44	0	
74	Evolocumab e outcome clinici in pazienti con patologia cardiovascolare. *L Endocrinologo*, **2017**, 18, 141-142		
73	Effects of a New Nutraceutical Formulation (Berberine, Red Yeast Rice and Chitosan) on Non-HDL Cholesterol Levels in Individuals with Dyslipidemia: Results from a Randomized, Double Blind, Placebo-Controlled Study. *International Journal of Molecular Sciences*, **2017**, 18,	6.3	36
72	A Novel Insulin/Glucose Model after a Mixed-Meal Test in Patients with Type 1 Diabetes on Insulin Pump Therapy. *Scientific Reports*, **2016**, 6, 36029	4.9	8
71	Sicurezza ed efficacia della liraglutide in pazienti con steatoepatite non alcolica (LEAN): uno studio di fase 2, multicentrico, doppio cieco, randomizzato, con controllo placebo. *L Endocrinologo*, **2016**, 17, 174-175	0	
70	In vivo imaging of beta cells with radiotracers: state of the art, prospects and recommendations for development and use. *Diabetologia*, **2016**, 59, 1340-1349	10.3	55
69	L accesso di mortalit nelle persone con diabete di tipo 2. *L Endocrinologo*, **2016**, 17, 55-56	0	
68	Interleukin-6 as a potential positive modulator of human beta-cell function: an exploratory analysis-the Verona Newly Diagnosed Type 2 Diabetes Study (VNDS) 6. *Acta Diabetologica*, **2016**, 53, 393-402	3.9	3
67	Effects on Nitric Oxide Production of Urolithins, Gut-Derived Ellagitannin Metabolites, in Human Aortic Endothelial Cells. *Molecules*, **2016**, 21,	4.8	25
66	Semaglutide ed esiti cardiovascolari in pazienti con diabete di tipo 2. *L Endocrinologo*, **2016**, 17, 270-271	0	
65	Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. *European Heart Journal Supplements*, **2016**, 18, C2-C12	1.5	56
64	Is common genetic variation at IRS1, ENPP1 and TRIB3 loci associated with cardiometabolic phenotypes in type 2 diabetes? An exploratory analysis of the Verona Newly Diagnosed Type 2 Diabetes Study (VNDS) 5. *Nutrition, Metabolism and Cardiovascular Diseases*, **2016**, 26, 232-8	4.5	5
63	Telomere length is independently associated with subclinical atherosclerosis in subjects with type 2 diabetes: a cross-sectional study. *Acta Diabetologica*, **2016**, 53, 661-7	3.9	14
62	The cell burden index of food: A proposal. *Nutrition, Metabolism and Cardiovascular Diseases*, **2016**, 26, 872-8	4.5	1

61	Islet Volume and Indexes of Cell Function in Humans. *Cell Transplantation*, **2016**, 25, 491-501	4	2
60	Treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short-acting and other glucagon-like peptide-1 receptor agonists. *Diabetes/Metabolism Research and Reviews*, **2016**, 32, 497-511	7.5	14
59	Prevalence of Cardiovascular Autonomic Neuropathy in a Cohort of Patients With Newly Diagnosed Type 2 Diabetes: The Verona Newly Diagnosed Type 2 Diabetes Study (VNDS). *Diabetes Care*, **2015**, 38, 1487-93	14.6	42
58	Association of a 62 Variants Type 2 Diabetes Genetic Risk Score With Markers of Subclinical Atherosclerosis: A Transethnic, Multicenter Study. *Circulation: Cardiovascular Genetics*, **2015**, 8, 507-15		11
57	A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy. *Atherosclerosis Supplements*, **2015**, 19, 1-12	1.7	50
56	Contribution of cell dysfunction and insulin resistance to cirrhosis-associated diabetes: Role of severity of liver disease. *Journal of Hepatology*, **2015**, 63, 1484-90	13.4	38
55	Sitagliptin ed esiti cardiovascolari nel diabete di tipo 2. *L Endocrinologo*, **2015**, 16, 234-235	0	
54	Effects of TiO and CoO nanoparticles on circulating angiogenic cells. *PLoS ONE*, **2015**, 10, e0119310	3.7	18
53	Transcriptomic analysis of human polarized macrophages: more than one role of alternative activation?. *PLoS ONE*, **2015**, 10, e0119751	3.7	46
52	Once-daily prandial lixisenatide versus once-daily rapid-acting insulin in patients with type 2 diabetes mellitus insufficiently controlled with basal insulin: analysis of data from five randomized, controlled trials. *Journal of Diabetes and Its Complications*, **2014**, 28, 40-4	3.2	28
51	Elevated 1-hour postload plasma glucose levels identify subjects with normal glucose tolerance but impaired cell function, insulin resistance, and worse cardiovascular risk profile: the GENFIEV study. *Journal of Clinical Endocrinology and Metabolism*, **2013**, 98, 2100-5	5.6	76
50	Role of reduced cell mass versus impaired cell function in the pathogenesis of type 2 diabetes. *Diabetes Care*, **2013**, 36 Suppl 2, S113-9	14.6	153
49	Cell lipotoxicity after an overnight intravenous lipid challenge and free fatty acid elevation in African American versus American white overweight/obese adolescents. *Journal of Clinical Endocrinology and Metabolism*, **2013**, 98, 2062-9	5.6	15
48	Cell lipotoxicity in response to free fatty acid elevation in prepubertal youth: African American versus Caucasian contrast. *Diabetes*, **2013**, 62, 2917-22	0.9	17
47	Identification of complex models of type 2 diabetes from IVGTT data by model-based design of experiments. *Computer Aided Chemical Engineering*, **2013**, 32, 133-138	0.6	
46	Pathogenetic mechanisms and cardiovascular risk: differences between HbA(1c) and oral glucose tolerance test for the diagnosis of glucose tolerance. *Diabetes Care*, **2012**, 35, 2607-12	14.6	34
45	CACNA1E variants affect beta cell function in patients with newly diagnosed type 2 diabetes. the Verona newly diagnosed type 2 diabetes study (VNDS) 3. *PLoS ONE*, **2012**, 7, e32755	3.7	20
44	Evidence for early defects in insulin sensitivity and secretion before the onset of glucose dysregulation in obese youths: a longitudinal study. *Diabetes*, **2012**, 61, 606-14	0.9	108

43	Metabolic effects of aerobic training and resistance training in type 2 diabetic subjects: a randomized controlled trial (the RAED2 study). *Diabetes Care*, **2012**, 35, 676-82	14.6	123
42	Very-low-calorie diet: a quick therapeutic tool to improve □cell function in morbidly obese patients with type 2 diabetes. *American Journal of Clinical Nutrition*, **2012**, 95, 609-13	7	76
41	Variants of GCKR affect both □cell and kidney function in patients with newly diagnosed type 2 diabetes: the Verona newly diagnosed type 2 diabetes study 2. *Diabetes Care*, **2011**, 34, 1205-10	14.6	27
40	Impact of reference category and number of traits in the cluster on risk of coronary heart disease in metabolic syndrome: prospective data from the Bruneck study. *Metabolic Syndrome and Related Disorders*, **2011**, 9, 313-8	2.6	1
39	Pleiotropic effects of GIP on islet function involve osteopontin. *Diabetes*, **2011**, 60, 2424-33	0.9	72
38	High-normal HbA1c is a strong predictor of type 2 diabetes in the general population. *Diabetes Care* , **2011**, 34, 1038-40	14.6	39
37	Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study. *Journal of Clinical Endocrinology and Metabolism*, **2010**, 95, 5028-36	5.6	112
36	Is the current therapeutic armamentarium in diabetes enough to control the epidemic and its consequences? What are the current shortcomings?. *Acta Diabetologica*, **2009**, 46, 173-81	3.9	19
35	Hyperinsulinemia and insulin resistance are independently associated with plasma lipids, uric acid and blood pressure in non-diabetic subjects. The GISIR database. *Nutrition, Metabolism and Cardiovascular Diseases*, **2008**, 18, 624-31	4.5	59
34	Metabolic abnormalities underlying the different prediabetic phenotypes in obese adolescents. *Journal of Clinical Endocrinology and Metabolism*, **2008**, 93, 1767-73	5.6	90
33	Impact of lowering the criterion for impaired fasting glucose on identification of individuals with insulin resistance. The GISIR database. *Diabetes/Metabolism Research and Reviews*, **2008**, 24, 130-6	7.5	5
32	Insulin sensitivity is correlated with subcutaneous but not visceral body fat in overweight and obese prepubertal children. *Journal of Clinical Endocrinology and Metabolism*, **2008**, 93, 2122-8	5.6	71
31	Fat cell size, insulin sensitivity, and inflammation in obese children. *Journal of Pediatrics*, **2007**, 151, 647-52	3.6	53
30	Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in caucasian subjects from the general population: the Bruneck study. *Diabetes Care*, **2007**, 30, 318-24	14.6	230
29	Muscle glucose transport and phosphorylation in type 2 diabetic, obese nondiabetic, and genetically predisposed individuals. *American Journal of Physiology - Endocrinology and Metabolism*, **2007**, 292, E92-100	6	59
28	Ghrelin, insulin sensitivity and postprandial glucose disposal in overweight and obese children. *European Journal of Endocrinology*, **2006**, 154, 61-8	6.5	35
27	Early impairment of beta-cell function and insulin sensitivity characterizes normotolerant Caucasian women with previous gestational diabetes. *Nutrition, Metabolism and Cardiovascular Diseases*, **2006**, 16, 485-93	4.5	8
26	Beta-cell function across the spectrum of glucose tolerance in obese youth. *Diabetes*, **2005**, 54, 1735-43	0.9	130

25	Population-based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck study. *Diabetes*, **2004**, 53, 1782-9	0.9	214
24	Alterations of glucose metabolism in type 2 diabetes mellitus. An overview. *Reviews in Endocrine and Metabolic Disorders*, **2004**, 5, 89-97	10.5	20
23	Carotid atherosclerosis and coronary heart disease in the metabolic syndrome: prospective data from the Bruneck study. *Diabetes Care*, **2003**, 26, 1251-7	14.6	246
22	Prediabetes in obese youth: a syndrome of impaired glucose tolerance, severe insulin resistance, and altered myocellular and abdominal fat partitioning. *Lancet, The*, **2003**, 362, 951-7	40	383
21	Vascular effects of insulin. A clinical physiologist's viewpoint. *International Congress Series*, **2003**, 1253, 191-195		
20	Prevalence, ancillary clinical features and cardiovascular disease in the metabolic syndrome: the Bruneck study. *International Congress Series*, **2003**, 1253, 13-17		1
19	Altered homeostatic adaptation of first- and second-phase beta-cell secretion in the offspring of patients with type 2 diabetes: studies with a minimal model to assess beta-cell function. *Diabetes*, **2003**, 52, 470-80	0.9	64
18	Insulin causes endothelial dysfunction in humans: sites and mechanisms. *Circulation*, **2002**, 105, 576-82	16.7	319
17	HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. *Diabetes Care*, **2002**, 25, 1135-41	14.6	390
16	ACE genotype and endothelium-dependent vasodilation of conduit arteries and forearm microcirculation in humans. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2001**, 21, 1313-9	9.4	17
15	Intracellular partition of plasma glucose disposal in hypertensive and normotensive subjects with type 2 diabetes mellitus. *Journal of Clinical Endocrinology and Metabolism*, **2001**, 86, 2073-9	5.6	8
14	Regulation of Muscle Glucose Uptake In Vivo **2001**, 803-845		4
13	Estimation of blood flow heterogeneity in human skeletal muscle using intravascular tracer data: importance for modeling transcapillary exchange. *Annals of Biomedical Engineering*, **1998**, 26, 764-74	4.7	9
12	Estimation of organ transport function for recirculating indicator dilution curves. *Annals of Biomedical Engineering*, **1998**, 26, 128-37	4.7	7
11	Role of tissue-specific blood flow and tissue recruitment in insulin-mediated glucose uptake of human skeletal muscle. *Circulation*, **1998**, 98, 234-41	16.7	132
10	Protein metabolism in human obesity: relationship with glucose and lipid metabolism and with visceral adipose tissue. *Journal of Clinical Endocrinology and Metabolism*, **1997**, 82, 2552-8	5.6	42
9	Cigarette smoking and insulin resistance in patients with noninsulin-dependent diabetes mellitus. *Journal of Clinical Endocrinology and Metabolism*, **1997**, 82, 3619-24	5.6	134
8	Estimation of blood flow heterogeneity distribution in human skeletal muscle from positron emission tomography data. *Annals of Biomedical Engineering*, **1997**, 25, 906-10	4.7	22

7	In vivo glucose transport in human skeletal muscle: tools, problems and perspectives. *Baillieres Clinical Endocrinology and Metabolism*, **1993**, 7, 929-60		13
6	The role of free fatty acid metabolism in the pathogenesis of insulin resistance in obesity and noninsulin-dependent diabetes mellitus. *Journal of Clinical Endocrinology and Metabolism*, **1991**, 72, 96-107	5.6	280
5	Effect of prolonged overnight fasting on energy metabolism in non-insulin-dependent diabetic and non-diabetic subjects. *European Journal of Endocrinology*, **1990**, 123, 30-6	6.5	11
4	Obesity and insulin resistance in humans: a dose-response study. *Metabolism: Clinical and Experimental*, **1990**, 39, 452-9	12.7	290
3	Acute elevation of free fatty acid levels leads to hepatic insulin resistance in obese subjects. *Metabolism: Clinical and Experimental*, **1987**, 36, 502-6	12.7	222
2	Insulin resistance in essential hypertension. *New England Journal of Medicine*, **1987**, 317, 350-7	59.2	2068
1	Loss of ZnT8 function protects against diabetes by enhanced insulin secretion		3